
|Videos|November 17, 2021
Pharmacist Medication Insights: Hizentra for Primary Immunodeficiency
Author(s)Saro Arakelians, PharmD
Hizentra is indicated for the treatment of primary immunodeficiency in adults and pediatric patients 2 years of age and older and maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy.
Advertisement
Hizentra is an immune globulin subcutaneous (Human) (IGSC), 20%. It is indicated for the treatment of primary immunodeficiency (PI) in adults and pediatric patients 2 years of age and older and maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Beyond Cost Avoidance: Advancing Unit-Level Pharmaceutical Economics in Health Systems
2
Pharmacist Care Gets BP Patients to Goal Faster, Safer
3
Higher Pulmonary Microplastic Burden Observed in Patients With Lung Cancer
4
Adult Pneumococcal Immunizations: A Practical Guide for Pharmacists
5



































































































